The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 2: 237 - 241

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.02.019

Drugs and Clinic Practice

Effects of simethicone on gastrointestinal hormones， intestinal floras and inflammatory process mediated by NLRP3 inflammasome in patients with irritable bowel syndrome

  • Xin LING ,
  • Jiaping QIAN ,
  • Dongtao SHI ,
  • Jun YANG ,
  • Peili FEI
Expand
  • Department of Gastroenterology，Suzhou Ninth People's Hospital，Suzhou 215200，China

Received date: 2023-09-21

  Online published: 2024-03-06

Fold

Abstract

Objective To explore the effects of simethicone on gastrointestinal hormones， intestinal floras and inflammatory process mediated by NOD?like receptor protein 3 （NLRP3） inflammasome in patients with irritable bowel syndrome （IBS）. Methods A total of 120 patients with IBS admitted to the hospital were prospectively enrolled as the research objects between January 1， 2021 and December 31， 2022， and they were randomly divided into control group （60 cases） and treatment group （60 cases）. The control group was treated with compound eosinophil?Lactobacillus， while treatment group was additionally treated with simethicone. The curative effect after treatment， scores of gastrointestinal symptom rating scale （GSRS）， levels of somatostatin （SS）， vasoactive intestinal peptide （VIP）， NLRP3 inflammasome， interleukin?8 （IL?8） and interleukin?1β （IL?1β）， counts of intestinal floras before and after treatment， and safety during treatment were compared between the two groups. Results After treatment， total response rate of treatment group was higher than that of control group （91.67% vs. 76.67%， P < 0.05）. After treatment， GSRS scores in both groups were decreased， which were lower in treatment group than control group （P < 0.05）. After treatment， levels of SS and VIP in both groups were decreased， which were lower in treatment group than control group （P < 0.05）. After treatment， counts of eosinophil?Lactobacillus and Bifidobacteria were increased in both groups， the difference was statistically significant （P < 0.05）， but there was no significant difference in counts of intestinal floras between the two groups （P > 0.05）. After treatment， levels of NLRP3 inflammasome， IL?8 and IL?1β were decreased in both groups， the difference was statistically significant （P < 0.05）， but there was no significant difference between the two groups （P > 0.05）. During treatment， there was no significant difference in side effects between the two groups （P > 0.05）. Conclusion Simethicone can significantly improve response rate of treatment， improve gastrointestinal symptoms and gastrointestinal hormones in IBS patients， which has no significant effects on intestinal floras and inflammatory process mediated by NLRP3 inflammasome， with good safety.

Key words： simethicone; irritable bowel syndrome; gastrointestinal hormone; NOD?like receptor protein 3 inflammasome

Cite this article

Xin LING , Jiaping QIAN , Dongtao SHI , Jun YANG , Peili FEI . Effects of simethicone on gastrointestinal hormones， intestinal floras and inflammatory process mediated by NLRP3 inflammasome in patients with irritable bowel syndrome[J]. The Journal of Practical Medicine, 2024 , 40(2) : 237 -241 . DOI: 10.3969/j.issn.1006-5725.2024.02.019

References

1 GOODOORY V C， NG C E， BLACK C J， et al. Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome［J］. Aliment Pharmacol Ther， 2022， 55（10）：1311-1319. doi:10.1111/apt.16816
2 BHATT R R， GUPTA A， LABUS J S， et al. A neuropsychosocial signature predicts longitudinal symptom changes in women with irritable bowel syndrome［J］. Mol Psychiatry， 2022， 27（3）：1774-1791. doi:10.1038/s41380-021-01375-9
3 CAMILLERI M， CARLSON P， BOUSABA J， et al. Comparison of biochemical， microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea［J］. Gut， 2023， 72（1）：54-65. doi:10.1136/gutjnl-2022-327471
4 YANG H， LIU X， PENG W， et al. Lipi Guben decoction in treating diarrheal irritable bowel syndrome： A study protocol for a randomized controlled trial［J］. Medicine （Baltimore）， 2021， 100（3）：e23887-e23887. doi:10.1097/md.0000000000023887
5 宋小平， 陈显韬， 敬秀平. 加味逍遥散联合双歧杆菌三联活菌胶囊治疗肠易激综合征的临床疗效及对肠道微生态功能的影响［J］. 解放军医药杂志， 2020， 32（2）：84-87，92. doi:10.3969/j.issn.2095-140X.2020.02.021
6 胡先平， 马锐. 复方嗜酸乳杆菌联合匹维溴铵治疗腹泻型肠易激综合征效果观察［J］. 现代消化及介入诊疗， 2018， 23（3）：359-361. doi:10.3969/j.issn.1672-2159.2018.03.032
7 谭林， 杨培. 5-HT4受体激动剂联合西甲硅油治疗非溃疡性消化不良的效果观察［J］. 广东医学， 2021， 42（3）：331-334.
8 DROSSMAN D A. The functional gastrointestinal disorders and the Rome III process［J］. Gastroenterology， 2006， 130（5）：1377-1390. doi:10.1053/j.gastro.2006.03.008
9 SINGH P， NEE J. Role of Diet in Diarrhea-predominant Irritable Bowel Syndrome［J］. J Clin Gastroenterol， 2021， 55（1）：25-29. doi:10.1097/mcg.0000000000001445
10 PORCELLI P， DE CARNE M， TODARELLO O. Prediction of treatment outcome of patients with functional gastrointestinal disorders by the diagnostic criteria for psychosomatic research［J］. Psychother Psychosom， 2004， 73（3）：166-173. doi:10.1159/000076454
11 ZHANG C Y， YAO X， SUN G， et al. Close association between abnormal expressed enzymes of energy metabolism and diarrhea-predominant irritable bowel syndrome［J］. Chin Med J （Engl）， 2019， 132（2）：135-144. doi:10.1097/cm9.0000000000000003
12 KOLOSKI N A， JONES M， WALKER M M， et al. Sleep disturbances in the irritable bowel syndrome and functional dyspepsia are independent of psychological distress： a population-based study of 1322 Australians［J］. Aliment Pharmacol Ther， 2021， 54（5）：627-636. doi:10.1111/apt.16500
13 L?VDAHL J， T?RNBLOM H， RINGSTR?M G， et al. Randomised clinical trial： individual versus group hypnotherapy for irritable bowel syndrome［J］. Aliment Pharmacol Ther， 2022， 55（12）：1501-1511. doi:10.1111/apt.16934
14 CHEY W D， KEEFER L， WHELAN K， et al. Behavioral and Diet Therapies in Integrated Care for Patients With Irritable Bowel Syndrome［J］. Gastroenterology， 2021， 160（1）：47-62. doi:10.1053/j.gastro.2020.06.099
15 SPERBER A D. Epidemiology and Burden of Irritable Bowel Syndrome： An International Perspective［J］. Gastroenterol Clin North Am， 2021， 50（3）：489-503. doi:10.1016/j.gtc.2021.04.001
16 谢宁， 李曼， 唐鄂. 胆舒胶囊联合酪酸梭菌活菌片治疗肠易激综合征的临床疗效［J］. 中国新药与临床杂志， 2018， 37（11）：651-654.
17 王少鑫， 崔立红， 弓三东， 等. 西甲硅油联合枯草杆菌肠球菌对肠易激综合征的疗效观察［J］. 现代生物医学进展， 2017， 17（6）：1102-1105.
18 HOLVOET T， JOOSSENS M， VáZQUEZ-CASTELLANOS J F， et al. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating： Short- and Long-term Results From a Placebo-Controlled Randomized Trial［J］. Gastroenterology， 2021， 160（1）：145-157. doi:10.1053/j.gastro.2020.07.013
19 王赛珊. 复方嗜酸乳杆菌片联合乳果糖对便秘型肠易激综合征患者肠道菌群的影响［J］. 重庆医学， 2022， 51（1）：267-269.
20 王洋， 黎晓琴， 史思文， 等. 聚乙二醇联合西甲硅油对结肠镜检查患者Boston肠道准备量表评分及耐受度的影响［J］. 中国综合临床， 2021， 37（5）：411-415. doi:10.3760/cma.j.cn101721-20201117-00050
21 郝芙蓉. 子宫肌瘤术后胃肠功能紊乱经平胃散、西甲硅油联合治疗的效果分析［J］. 现代消化及介入诊疗， 2019， 24（6）：629-631. doi:10.3969/j.issn.1672-2159.2019.06.016
22 王波， 林建霞， 王鹏. 枯草杆菌肠球菌二联活菌对便秘型肠易激综合征患者 胃肠激素及IL-18、IL-23、TNF-α水平的影响［J］. 贵州医药， 2021， 45（6）：871-872.
23 赵峰， 刘露， 孙颖， 等. Hp感染对慢性胃炎患者胃黏膜病变和miR-22与NLRP3炎症小体和肠道菌群的影响［J］. 中华医院感染学杂志， 2022， 32（19）：2940-2944.
24 韩棉梅， 马军， 宋雨鸿， 等. 结肠灵通过调节NLRP3炎性小体活化对感染后肠易激综合征大鼠内脏敏感性的机制研究［J］. 胃肠病学和肝病学杂志， 2020， 29（10）：1145-1150. doi:10.3969/j.issn.1006-5709.2020.10.014
Options
Outlines

/

〈 〉